manop / Shutterstock.com
As reflected in numerous recent court opinions, the broad Supreme Court rulings of Mayo, Myriad and Alice have drastically changed the landscape of patent-eligibility in diagnostics. Jenny Shmuel and Megan Chacon of Fish & Richardson review the situation and discuss some future scenarios.
The patent eligibility landscape under 35 USC §101 has shifted in the past few years, with the courts issuing a series of decisions which threaten to undermine a system designed to encourage and reward innovation and development. The application of this law in one particular area—screening and diagnostic testing during and after pregnancy—highlights the unprecedented difficulty faced by those seeking patent protection in the life sciences arena and points to a potential turning point in the law.
Where we have come from
More than 35 years ago, the Supreme Court in Diamond v Chakrabarty (1980) held that a live, human-made microorganism was patent-eligible subject matter, setting the tone for the next 30 years for the liberal grant of a multitude of life sciences-related patents. However, the Supreme Court’s recent rulings on patent eligibility have moved in a very different direction.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Jenny Shmuel, Megan Chacon, Fish & Richardson, Ariosa, Mayo, Myriad, Alice, PTAB, US Patent and Trademark Office, patent, CLS Bank, DNA,